Dexamethasone-based Mouthwash for Stomatitis Prevention

Share this content:
Prophylactic use of dexamethasone-based mouthwash substantially reduced the incidence and severity of stomatitis.
Prophylactic use of dexamethasone-based mouthwash substantially reduced the incidence and severity of stomatitis.

Prophylactic use of dexamethasone-based mouthwash substantially reduced the incidence and severity of stomatitis among patients with metastatic breast cancer receiving exemestane and everolimus, according to a study presented at the 2016 Palliative Care in Oncology Symposium.1

Patients receiving everolimus frequently report stomatitis, with 33% of patients treated with everolimus and exemestane reporting grade 2 or worse stomatitis in the BOLERO-2 trial. Researchers evaluated dexamethasone-based mouthwash for the prevention of stomatitis among these patients.

For the SWISH study, investigators enrolled 92 patients with hormone receptor-positive metastatic breast cancer receiving everolimus plus exemestane. Participants were instructed to use 10 mL of commercially available dexamethasone 0.5 mg/5 mL solution 4 times per day for 8 weeks beginning on day 1 of chemotherapy.

Among the 86 evaluable patients, the rate of all grade stomatitis at 8 weeks was 21.2%, and the rate of grade 2 or worse stomatitis was 2.4%. There were no cases of grade 3 or 4 stomatitis.

Nearly 90% of patients maintained or had improved ECOG performance status and the average pain scale score was less than 1 at all visits. The same proportion of patients reported eating a normal diet at 8 weeks.

RELATED: Breast Cancer Risk and Psychosocial Adjustment Among Adolescents

The findings suggest that dexamethasone-based mouthwash should be considered a new standard for stomatitis prevention in this patient population.                                      

Reference

  1. Rugo HS, Beck JT, Glaspy JA, et al. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. Poster presented at: 2016 Palliative Care in Oncology Symposium; September 9-10, 2016; San Francisco, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters